What is Aquestive Therapeutics, Inc.'s deferred revenue?

Aquestive Therapeutics, Inc. (AQST) reported deferred revenue of -$272K in Q1 2026.

How has Aquestive Therapeutics, Inc.'s deferred revenue changed year-over-year?

Aquestive Therapeutics, Inc.'s deferred revenue decreased by 4.2% year-over-year, from -$261K to -$272K.

What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred revenue?

Over 2 years (2021 to 2024), Aquestive Therapeutics, Inc.'s deferred revenue has grown at a 84.9% compound annual growth rate (CAGR), from $3.76M to -$12.84M.

Aquestive Therapeutics, Inc. AQST Deferred Revenue

Deferred Revenue at other companies

RegenxbioRGNX

——

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s deferred revenue?: Aquestive Therapeutics, Inc. (AQST) reported deferred revenue of -$272K in Q1 2026.
How has Aquestive Therapeutics, Inc.'s deferred revenue changed year-over-year?: Aquestive Therapeutics, Inc.'s deferred revenue decreased by 4.2% year-over-year, from -$261K to -$272K.
What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred revenue?: Over 2 years (2021 to 2024), Aquestive Therapeutics, Inc.'s deferred revenue has grown at a 84.9% compound annual growth rate (CAGR), from $3.76M to -$12.84M.